Home / About Peptonic / The Board

Board of Directors

Hans von Celsing

Chairman of the Board.
Mr. Hans von Celsing serves as Business Advisor at NeuroVentures Capital LLC. Mr. Von Celsing serves as Executive Director of Business Development of Gelexir Healthcare Ltd. He served as Executive Vice President of Elekta Holdings U.S., Inc. and Elekta AB. He has 25 years of entrepreneurial, managerial and board experience from the Medical Technology Industry including spinal and neurosurgery. He serves as Director of Clinical Laserthermia Systems AB. He serves as a Director of Gelexir Healthcare Ltd.He graduated from Harvard Business School.

Leni Ekendahl

Leni Ekendahl

Member of the Board.
Self-employed, Injecta Impact Investments AB.
Investor and adviser in Impact Investments. Collaborates with, among other things, Keiretsu Nordic Business Angels.

Marianne Östlund

Marianne Östlund

Member of the Board.
Shareholder and founder of the PR section in Effective Media AB.
Positions of trust in Effektiva Media  AB, Jerntorget AB, Mora Järn och Bygg AB, Empire AB, 1,6 miljonersklubben, Mattias Klum AB.

Anna Tenstam, Member of the board

Anna Tenstam

Member of the Board.
Positions of trust/ bord member of Optomed Oyj, Datum Biotech Ltd, Sue Ellen Investments, Una Esthetics, AIA associations US.  Active in additionl business networks in Life Science globally. Active investor in several medtech companies globally.


Recent Comments

    All press releases on Spotlightstockmarket.com

    All published press releases from PEPTONIC medical is available on spotlightstockmarket.com.

    About us

    PEPTONIC Medical is an innovative Swedish pharmaceutical company developing and commercializing safe and effective products for the treatment of menopausal symptoms, such as vaginal atrophy. VagiVital® is a registered trademark of PEPTONIC Medical. The product is being commercialised for the non-prescription use for the treatment of vaginal atrophy.

    The Company was founded in 2009 and its first candidate drug product is Vagitocin® – an estrogen-free oxytocin based product for the treatment of vaginal atrophy in clinical development phase 2.

    Oxytocin has a long history of safe and effective medical use and offers an alternative to estrogen and estrogen-like acting compounds for menopausal and postmenopausal women.